In this study, we demonstrated the efficacy of the novel FLT3 inhibitor BPR1J-340 in various in vitro and in vivo models of AML and identify synergistic effects with HDACi SAHA on the cytotoxicity of FL3-ITD-expressing cells in in vitro analyses. The gene discussed is FLT3; the disease is acute myeloid leukemia.